BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Auclair AL, Martel JC, Assié MB, Bardin L, Heusler P, Cussac D, Marien M, Newman-Tancredi A, O’Connor JA, Depoortère R. Levomilnacipran (F2695), a norepinephrine-preferring SNRI: profile in vitro and in models of depression and anxiety. Neuropharmacology. 2013;70:338-347. [PMID: 23499664 DOI: 10.1016/j.neuropharm.2013.02.024] [Cited by in Crossref: 54] [Cited by in F6Publishing: 52] [Article Influence: 6.8] [Reference Citation Analysis]
Number Citing Articles
1 Asnis GM, Henderson MA. Levomilnacipran for the treatment of major depressive disorder: a review. Neuropsychiatr Dis Treat 2015;11:125-35. [PMID: 25657584 DOI: 10.2147/NDT.S54710] [Cited by in Crossref: 13] [Cited by in F6Publishing: 2] [Article Influence: 2.2] [Reference Citation Analysis]
2 Deardorff WJ, Grossberg GT. A review of the clinical efficacy, safety and tolerability of the antidepressants vilazodone, levomilnacipran and vortioxetine. Expert Opin Pharmacother 2014;15:2525-42. [PMID: 25224953 DOI: 10.1517/14656566.2014.960842] [Cited by in Crossref: 27] [Cited by in F6Publishing: 19] [Article Influence: 3.9] [Reference Citation Analysis]
3 Polychroniou PE, Mayberg HS, Craighead WE, Rakofsky JJ, Aponte Rivera V, Haroon E, Dunlop BW. Temporal Profiles and Dose-Responsiveness of Side Effects with Escitalopram and Duloxetine in Treatment-Naïve Depressed Adults. Behav Sci (Basel) 2018;8:E64. [PMID: 30018196 DOI: 10.3390/bs8070064] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
4 Raouf M, Glogowski AJ, Bettinger JJ, Fudin J. Serotonin-norepinephrine reuptake inhibitors and the influence of binding affinity (Ki) on analgesia. J Clin Pharm Ther 2017;42:513-7. [PMID: 28503727 DOI: 10.1111/jcpt.12534] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
5 Bokor G, Anderson PD. Obsessive-compulsive disorder. J Pharm Pract 2014;27:116-30. [PMID: 24576790 DOI: 10.1177/0897190014521996] [Cited by in Crossref: 29] [Cited by in F6Publishing: 20] [Article Influence: 4.1] [Reference Citation Analysis]
6 Wu L, Qiao Y, Wang L, Guo J, Wang G, He W, Yin L, Zhao J. A Self-microemulsifying Drug Delivery System (SMEDDS) for a Novel Medicative Compound Against Depression: a Preparation and Bioavailability Study in Rats. AAPS PharmSciTech 2015;16:1051-8. [PMID: 25652729 DOI: 10.1208/s12249-014-0280-y] [Cited by in Crossref: 33] [Cited by in F6Publishing: 21] [Article Influence: 5.5] [Reference Citation Analysis]
7 Saraceni MM, Venci JV, Gandhi MA. Levomilnacipran (Fetzima): A New Serotonin-Norepinephrine Reuptake Inhibitor for the Treatment of Major Depressive Disorder. Journal of Pharmacy Practice 2014;27:389-95. [DOI: 10.1177/0897190013516504] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 1.1] [Reference Citation Analysis]
8 Lee SM, Dong TS, Krause-Sorio B, Siddarth P, Milillo MM, Lagishetty V, Datta T, Aguilar-Faustino Y, Jacobs JP, Lavretsky H. The intestinal microbiota as a predictor for antidepressant treatment outcome in geriatric depression: a prospective pilot study. Int Psychogeriatr 2021;:1-13. [PMID: 33757609 DOI: 10.1017/S1041610221000120] [Reference Citation Analysis]
9 Zhao L, Guo R, Cao N, Lin Y, Yang W, Pei S, Ma X, Zhang Y, Li Y, Song Z, Du W, Xiao X, Liu C. An Integrative Pharmacology-Based Pattern to Uncover the Pharmacological Mechanism of Ginsenoside H Dripping Pills in the Treatment of Depression. Front Pharmacol 2020;11:590457. [PMID: 33658934 DOI: 10.3389/fphar.2020.590457] [Reference Citation Analysis]
10 Hu B, Doods H, Treede R, Ceci A. Duloxetine and 8-OH-DPAT, but not fluoxetine, reduce depression-like behaviour in an animal model of chronic neuropathic pain. Neuroscience Letters 2016;619:162-7. [DOI: 10.1016/j.neulet.2016.03.019] [Cited by in Crossref: 18] [Cited by in F6Publishing: 12] [Article Influence: 3.6] [Reference Citation Analysis]
11 Lukić I, Getselter D, Ziv O, Oron O, Reuveni E, Koren O, Elliott E. Antidepressants affect gut microbiota and Ruminococcus flavefaciens is able to abolish their effects on depressive-like behavior. Transl Psychiatry 2019;9:133. [PMID: 30967529 DOI: 10.1038/s41398-019-0466-x] [Cited by in Crossref: 45] [Cited by in F6Publishing: 33] [Article Influence: 22.5] [Reference Citation Analysis]
12 Shelton RC. Serotonin and Norepinephrine Reuptake Inhibitors. Handb Exp Pharmacol 2019;250:145-80. [PMID: 30838456 DOI: 10.1007/164_2018_164] [Cited by in Crossref: 30] [Cited by in F6Publishing: 20] [Article Influence: 15.0] [Reference Citation Analysis]
13 Eap CB, Gründer G, Baumann P, Ansermot N, Conca A, Corruble E, Crettol S, Dahl ML, de Leon J, Greiner C, Howes O, Kim E, Lanzenberger R, Meyer JH, Moessner R, Mulder H, Müller DJ, Reis M, Riederer P, Ruhe HG, Spigset O, Spina E, Stegman B, Steimer W, Stingl J, Suzen S, Uchida H, Unterecker S, Vandenberghe F, Hiemke C. Tools for optimising pharmacotherapy in psychiatry (therapeutic drug monitoring, molecular brain imaging and pharmacogenetic tests): focus on antidepressants. World J Biol Psychiatry 2021;:1-68. [PMID: 33977870 DOI: 10.1080/15622975.2021.1878427] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
14 Montgomery SA, Mansuy L, Ruth AC, Li D, Gommoll C. The efficacy of extended-release levomilnacipran in moderate to severe major depressive disorder: secondary and post-hoc analyses from a randomized, double-blind, placebo-controlled study. Int Clin Psychopharmacol 2014;29:26-35. [PMID: 24172160 DOI: 10.1097/YIC.0000000000000009] [Cited by in Crossref: 12] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
15 Bruno A, Morabito P, Spina E, Muscatello MR. The Role of Levomilnacipran in the Management of Major Depressive Disorder: A Comprehensive Review. Curr Neuropharmacol 2016;14:191-9. [PMID: 26572745 DOI: 10.2174/1570159x14666151117122458] [Cited by in Crossref: 12] [Cited by in F6Publishing: 4] [Article Influence: 2.4] [Reference Citation Analysis]
16 Köhler S, Cierpinsky K, Kronenberg G, Adli M. The serotonergic system in the neurobiology of depression: Relevance for novel antidepressants. J Psychopharmacol 2016;30:13-22. [DOI: 10.1177/0269881115609072] [Cited by in Crossref: 73] [Cited by in F6Publishing: 50] [Article Influence: 14.6] [Reference Citation Analysis]
17 Cosi C, Martel JC, Auclair AL, Collo G, Cavalleri L, Heusler P, Leriche L, Gaudoux F, Sokoloff P, Moser PC, Gatti-McArthur S. Pharmacology profile of F17464, a dopamine D3 receptor preferential antagonist. Eur J Pharmacol 2021;890:173635. [PMID: 33065094 DOI: 10.1016/j.ejphar.2020.173635] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
18 Brunner V, Maynadier B, Chen L, Roques L, Hude I, Séguier S, Barthe L, Hermann P. Disposition and metabolism of [14C]-levomilnacipran, a serotonin and norepinephrine reuptake inhibitor, in humans, monkeys, and rats. Drug Des Devel Ther 2015;9:3199-215. [PMID: 26150694 DOI: 10.2147/DDDT.S80886] [Cited by in Crossref: 4] [Article Influence: 0.7] [Reference Citation Analysis]
19 Sanfilippo C, Nicolosi G, Patti A. Milnacipran as a challenging example of aminomethyl substrate for lipase-catalyzed kinetic resolution. Journal of Molecular Catalysis B: Enzymatic 2014;104:82-6. [DOI: 10.1016/j.molcatb.2014.03.015] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
20 Simola N. Rat Ultrasonic Vocalizations and Behavioral Neuropharmacology: From the Screening of Drugs to the Study of Disease. Curr Neuropharmacol 2015;13:164-79. [PMID: 26411760 DOI: 10.2174/1570159x13999150318113800] [Cited by in Crossref: 53] [Cited by in F6Publishing: 15] [Article Influence: 10.6] [Reference Citation Analysis]
21 Palmer EC, Binns LN, Carey H. Levomilnacipran: A New Serotonin-Norepinephrine Reuptake Inhibitor for the Treatment of Major Depressive Disorder. Ann Pharmacother 2014;48:1030-9. [DOI: 10.1177/1060028014535074] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
22 Bakish D, Bose A, Gommoll C, Chen C, Nunez R, Greenberg WM, Liebowitz M, Khan A. Levomilnacipran ER 40 mg and 80 mg in patients with major depressive disorder: a phase III, randomized, double-blind, fixed-dose, placebo-controlled study. J Psychiatry Neurosci. 2014;39:40-49. [PMID: 24144196 DOI: 10.1503/jpn.130040] [Cited by in Crossref: 38] [Cited by in F6Publishing: 37] [Article Influence: 6.3] [Reference Citation Analysis]
23 Krause‐sorio B, Kilpatrick L, Siddarth P, Ercoli L, Laird KT, Aguilar‐faustino Y, Milillo MM, Narr KL, Lavretsky H. Cortical thickness increases with levomilnacipran treatment in a pilot randomised double‐blind placebo‐controlled trial in late‐life depression. Psychogeriatrics 2020;20:140-8. [DOI: 10.1111/psyg.12475] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
24 Scott LJ. Levomilnacipran Extended-Release: A Review of Its Use in Adult Patients with Major Depressive Disorder. CNS Drugs 2014;28:1071-82. [DOI: 10.1007/s40263-014-0203-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
25 Wyska E. Pharmacokinetic considerations for current state-of-the-art antidepressants. Expert Opinion on Drug Metabolism & Toxicology 2019;15:831-47. [DOI: 10.1080/17425255.2019.1669560] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
26 Chen L, Boinpally R, Gad N, Greenberg WM, Wangsa J, Periclou A, Ghahramani P. Evaluation of Cytochrome P450 (CYP) 3A4-Based Interactions of Levomilnacipran with Ketoconazole, Carbamazepine or Alprazolam in Healthy Subjects. Clin Drug Investig 2015;35:601-12. [DOI: 10.1007/s40261-015-0318-2] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
27 Thase ME, Gommoll C, Chen C, Kramer K, Sambunaris A. Effects of levomilnacipran extended-release on motivation/energy and functioning in adults with major depressive disorder. Int Clin Psychopharmacol 2016;31:332-40. [PMID: 27455513 DOI: 10.1097/YIC.0000000000000138] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
28 Brum ES, Becker G, Fialho MFP, Oliveira SM. Animal models of fibromyalgia: What is the best choice? Pharmacol Ther 2021;:107959. [PMID: 34265360 DOI: 10.1016/j.pharmthera.2021.107959] [Reference Citation Analysis]
29 Chen L, Greenberg WM, Gommoll C, O’connor J, Zukin SR, Periclou A, Ghahramani P. Levomilnacipran Pharmacokinetics in Healthy Volunteers Versus Patients with Major Depressive Disorder and Implications for Norepinephrine and Serotonin Reuptake Inhibition. Clinical Therapeutics 2015;37:2059-70. [DOI: 10.1016/j.clinthera.2015.07.005] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
30 He H, Wang W, Lyu J, Zheng J, Guo L, An X, Fan Y, Ma X. Efficacy and tolerability of different doses of three new antidepressants for treating major depressive disorder: A PRISMA-compliant meta-analysis. Journal of Psychiatric Research 2018;96:247-59. [DOI: 10.1016/j.jpsychires.2017.10.018] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
31 McIntyre RS. The role of new antidepressants in clinical practice in Canada: a brief review of vortioxetine, levomilnacipran ER, and vilazodone. Neuropsychiatr Dis Treat 2017;13:2913-9. [PMID: 29238196 DOI: 10.2147/NDT.S150589] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
32 Sambunaris A, Gommoll C, Chen C, Greenberg WM. Efficacy of levomilnacipran extended-release in improving functional impairment associated with major depressive disorder: pooled analyses of five double-blind, placebo-controlled trials. Int Clin Psychopharmacol 2014;29:197-205. [PMID: 24667487 DOI: 10.1097/YIC.0000000000000033] [Cited by in Crossref: 16] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
33 Cutler AJ, Gommoll CP, Chen C, Greenberg WM, Ruth A. Levomilnacipran Extended-Release Treatment in Patients With Major Depressive Disorder: Improvements in Functional Impairment Categories. Prim Care Companion CNS Disord 2015;17. [PMID: 26644957 DOI: 10.4088/PCC.14m01753] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
34 Citrome L. Levomilnacipran for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antidepressant--what is the number needed to treat, number needed to harm and likelihood to be helped or harmed? Int J Clin Pract. 2013;67:1089-1104. [PMID: 24016209 DOI: 10.1111/ijcp.12298] [Cited by in Crossref: 32] [Cited by in F6Publishing: 22] [Article Influence: 4.0] [Reference Citation Analysis]
35 Gommoll CP, Greenberg WM, Chen C. A randomized, double-blind, placebo-controlled study of flexible doses of levomilnacipran ER (40-120 mg/day) in patients with major depressive disorder. J Drug Assess 2014;3:10-9. [PMID: 27536449 DOI: 10.3109/21556660.2014.884505] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 3.1] [Reference Citation Analysis]
36 Montgomery SA, Gommoll CP, Chen C, Greenberg WM. Efficacy of levomilnacipran extended-release in major depressive disorder: pooled analysis of 5 double-blind, placebo-controlled trials. CNS Spectr 2015;20:148-56. [PMID: 24902007 DOI: 10.1017/S1092852914000273] [Cited by in Crossref: 14] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
37 Malikowska N, Fijałkowski Ł, Nowaczyk A, Popik P, Sałat K. Antidepressant-like activity of venlafaxine and clonidine in mice exposed to single prolonged stress - A model of post-traumatic stress disorder. Pharmacodynamic and molecular docking studies. Brain Res 2017;1673:1-10. [PMID: 28797691 DOI: 10.1016/j.brainres.2017.08.001] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 2.8] [Reference Citation Analysis]
38 Talele TT. The "Cyclopropyl Fragment" is a Versatile Player that Frequently Appears in Preclinical/Clinical Drug Molecules. J Med Chem 2016;59:8712-56. [PMID: 27299736 DOI: 10.1021/acs.jmedchem.6b00472] [Cited by in Crossref: 314] [Cited by in F6Publishing: 140] [Article Influence: 62.8] [Reference Citation Analysis]
39 Montoya A, Bruins R, Katzman MA, Blier P. The noradrenergic paradox: implications in the management of depression and anxiety. Neuropsychiatr Dis Treat 2016;12:541-57. [PMID: 27042068 DOI: 10.2147/NDT.S91311] [Cited by in Crossref: 26] [Cited by in F6Publishing: 11] [Article Influence: 5.2] [Reference Citation Analysis]
40 Huang Q, Zhong X, Yun Y, Yu B, Huang Y. Efficacy and safety of multiple doses of levomilnacipran extended-release for the treatment of major depressive disorder. Neuropsychiatr Dis Treat 2016;12:2707-14. [PMID: 27822042 DOI: 10.2147/NDT.S114955] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
41 Blier P, Gommoll C, Chen C, Kramer K. Effects of levomilnacipran ER on noradrenergic symptoms, anxiety symptoms, and functional impairment in adults with major depressive disorder: Post hoc analysis of 5 clinical trials. Journal of Affective Disorders 2017;210:273-9. [DOI: 10.1016/j.jad.2016.11.011] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
42 Hair P, Cameron F, Garnock-Jones KP. Levomilnacipran extended release: first global approval. Drugs 2013;73:1639-45. [PMID: 24000002 DOI: 10.1007/s40265-013-0116-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
43 Xue W, Yang F, Wang P, Zheng G, Chen Y, Yao X, Zhu F. What Contributes to Serotonin–Norepinephrine Reuptake Inhibitors’ Dual-Targeting Mechanism? The Key Role of Transmembrane Domain 6 in Human Serotonin and Norepinephrine Transporters Revealed by Molecular Dynamics Simulation. ACS Chem Neurosci 2018;9:1128-40. [DOI: 10.1021/acschemneuro.7b00490] [Cited by in Crossref: 92] [Cited by in F6Publishing: 73] [Article Influence: 30.7] [Reference Citation Analysis]
44 Mago R, Mahajan R, Thase ME. Levomilnacipran: a newly approved drug for treatment of major depressive disorder. Expert Review of Clinical Pharmacology 2014;7:137-45. [DOI: 10.1586/17512433.2014.889563] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 2.3] [Reference Citation Analysis]
45 Mago R, Forero G, Greenberg WM, Gommoll C, Chen C. Safety and tolerability of levomilnacipran ER in major depressive disorder: results from an open-label, 48-week extension study. Clin Drug Investig. 2013;33:761-771. [PMID: 23999912 DOI: 10.1007/s40261-013-0126-5] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 2.6] [Reference Citation Analysis]
46 Roman MW, Wilkinson SM. Vortioxetine (Brintellix ® ) and Levomilnacipran (Fetzima ® ): The Two Newest Additions to the Antidepressant Formulary. Issues in Mental Health Nursing 2014;35:972-4. [DOI: 10.3109/01612840.2014.955155] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
47 Sharma H, Santra S, Dutta A. Triple reuptake inhibitors as potential next-generation antidepressants: a new hope? Future Med Chem 2015;7:2385-406. [PMID: 26619226 DOI: 10.4155/fmc.15.134] [Cited by in Crossref: 20] [Cited by in F6Publishing: 14] [Article Influence: 3.3] [Reference Citation Analysis]
48 Blum SI, Tourkodimitris S, Ruth A. Evaluation of functional health and well-being in patients receiving levomilnacipran ER for the treatment of major depressive disorder. Journal of Affective Disorders 2015;170:230-6. [DOI: 10.1016/j.jad.2014.09.005] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
49 Ding HX, Leverett CA, Kyne RE, Liu KK, Fink SJ, Flick AC, O’donnell CJ. Synthetic approaches to the 2013 new drugs. Bioorganic & Medicinal Chemistry 2015;23:1895-922. [DOI: 10.1016/j.bmc.2015.02.056] [Cited by in Crossref: 43] [Cited by in F6Publishing: 21] [Article Influence: 7.2] [Reference Citation Analysis]
50 Sambunaris A, Bose A, Gommoll CP, Chen C, Greenberg WM, Sheehan DV. A phase III, double-blind, placebo-controlled, flexible-dose study of levomilnacipran extended-release in patients with major depressive disorder. J Clin Psychopharmacol. 2014;34:47-56. [PMID: 24172209 DOI: 10.1097/jcp.0000000000000060] [Cited by in Crossref: 47] [Cited by in F6Publishing: 17] [Article Influence: 6.7] [Reference Citation Analysis]
51 Deardorff WJ, Grossberg GT. The Pharmacology and Clinical Use of the Antidepressants Vilazodone, Levomilnacipran, and Vortioxetine for Depression in the Elderly. Curr Geri Rep 2015;4:301-11. [DOI: 10.1007/s13670-015-0140-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
52 Robinson DJ, Coons M, Haensel H, Vallis M, Yale JF; Diabetes Canada Clinical Practice Guidelines Expert Committee. Diabetes and Mental Health. Can J Diabetes 2018;42 Suppl 1:S130-41. [PMID: 29650085 DOI: 10.1016/j.jcjd.2017.10.031] [Cited by in Crossref: 22] [Cited by in F6Publishing: 14] [Article Influence: 7.3] [Reference Citation Analysis]